Brief: Vor Bio Announces Exploration Of Strategic Alternatives To Maximize Shareholder Value
08/05/2025 16:04
May 8 (Reuters) - Vor Biopharma Inc VOR.O: VOR BIO ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE VOR BIOPHARMA INC - BIO IMPLEMENTS 95% WORKFORCE REDUCTION COSTING $10.9 MILLION VOR BIOPHARMA INC - STRATEGIC ALTERNATIVES INCLUDE SALE, LICENSING, MERGER VOR BIOPHARMA INC: PLANS TO RETAIN ABOUT 8 EMPLOYEES TO ASSIST IN EXPLORING STRATEGIC ALTERNATIVES VOR BIOPHARMA INC: ALSO WINDING DOWN ITS CLINICAL AND MANUFACTURING OPERATIONS, BEGINNING IMMEDIATELY, INCLUDING ITS ONGOING CLINICAL TRIALS Source text: ID:nGNXbN7GWh Further company coverage: VOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning